Lv Junfeng, Yang Lixin, Qu Shenghua, Meng Runze, Li Qingxiangzi, Liu Huicong, Wang Xiaoyan, Zhang Dabing
Key Laboratory of Animal Epidemiology and Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Front Vet Sci. 2019 Dec 10;6:442. doi: 10.3389/fvets.2019.00442. eCollection 2019.
Neutralizing antibodies are the key mediators of protective immune response to flaviviruses after both infection and vaccination. Plaque reduction neutralization test (PRNT) is considered the "gold standard" for measurement of the immunity. To date, little is known regarding neutralizing antibody response to Tembusu virus (TMUV), a novel flavivirus emerging in ducks in 2010. Here, we developed a PRNT for detection of TMUV neutralizing antibodies. Following optimization and validation, the PRNT was applied to test serum samples from different flocks of ducks. Using sera prepared in experimental conditions, the levels of 50% end point titer (neutralizing dose, ND) generated from positive sera (5,012-79,433) were significantly higher than those from mock-infected sera (10 to 126), indicating that the test can be used in the detection of TMUV-specific neutralizing antibodies. Dose-dependent efficacy test of a cell-derived 180th passage of a plaque-purified virus of the PS TMUV isolate (PS180) in combined with immunization-challenge experiments revealed that ND titer of ~1,258 is the minimum capable of providing adequate protection against challenge with virulent TMUV. In the investigation of serum samples collected from three flocks infected by TMUV and four flocks vaccinated with a licensed attenuated vaccine (the 120th passage virus), ND titers peaked at 1 week after both disease onset (7,943-125,893) and vaccination (3,612-79,432), and high levels of ND titer were detected in sera collected at 15 weeks after disease onset (5,012-63,095) and 17 weeks after vaccination (3,981-25,119). Together these findings demonstrated that spontaneous and experimental infections by TMUV and vaccination with the licensed TMUV attenuated vaccine elicit high, long-lasting neutralizing antibodies. The highest ND titer of neutralizing antibodies elicited by PS180 was determined to be 3,162, suggesting that attenuation of TMUV by more passages has a dramatic impact on the neutralizing antibody response of the virus.
中和抗体是感染和接种疫苗后对黄病毒产生保护性免疫反应的关键介质。空斑减少中和试验(PRNT)被认为是衡量免疫力的“金标准”。迄今为止,关于对坦布苏病毒(TMUV)的中和抗体反应知之甚少,TMUV是2010年在鸭群中出现的一种新型黄病毒。在此,我们开发了一种用于检测TMUV中和抗体的PRNT。经过优化和验证后,该PRNT被应用于检测不同鸭群的血清样本。使用在实验条件下制备的血清,阳性血清(5,012 - 79,433)产生的50%终点滴度(中和剂量,ND)水平显著高于 mock 感染血清(10至126),表明该试验可用于检测TMUV特异性中和抗体。PS TMUV分离株(PS180)的空斑纯化病毒第180代细胞衍生株与免疫攻毒实验相结合的剂量依赖性效力试验表明,~1,258的ND滴度是能够提供足够保护以抵抗强毒TMUV攻毒的最低滴度。在对三个感染TMUV的鸭群和四个接种许可减毒疫苗(第120代病毒)的鸭群采集的血清样本进行调查时,疾病发作(7,943 - 125,893)和接种疫苗(3,612 - 79,432)后1周时ND滴度均达到峰值,并且在疾病发作后15周(5,012 - 63,095)和接种疫苗后17周(3,981 - 25,119)采集的血清中检测到高水平的ND滴度。这些发现共同表明,TMUV的自然感染和实验性感染以及接种许可的TMUV减毒疫苗均可引发高且持久的中和抗体。PS180引发的中和抗体的最高ND滴度被确定为3,162,这表明更多代次传代对TMUV进行减毒会对病毒的中和抗体反应产生显著影响。